

April 15, 2024

The Listing Department BSE Limited Phiroze Jeejebhoy Towers, Dalal Street, Fort, Mumbai – 400001 BSE Scrip Code: 543427 The Listing Department National Stock Exchange of India Limited Exchange Plaza, 5<sup>th</sup> Floor Plot No. C/1, G Block, Bandra - Kurla Complex Bandra (East), Mumbai – 400051 NSE Symbol: MEDPLUS

Dear Sir/Madam,

## Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform that one of the subsidiary of the Company i.e., Optival Health Solutions Private Limited has received certain orders from the office of the Assistant Drug Commissioner, Drugs Control Administration, Nashik under Drugs and Cosmetic Act, 1940 and Drugs and Cosmetics Rules, 1945. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details are provided below:

Name(s) of the Authority:	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad- interim or interim orders, or any other communication from the authority	violation(s) / contravention(s) committed or	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Assistant Drug Commissioner, Drugs Control Administration, Nashik, Maharashtra	Apartment, Ashoka Marg,	Order dated April 8, 2024 received on April 13,2024.	Under Rule 66(1) under the Drug and Cosmetic Act, 1940 and Rules, 1945 Under Rule 65(2), 65(3)(1), 65(2), 65(4)(1), 65(11-A) under the Drug and Cosmetic Act, 1940 and Rules, 1945	Loss of Rs~ 1.80 Lacs.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava Company Secretary FCS 7460

